News
01-19-2011, 06:16 AM
Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).
More... (http://www.news-medical.net/news/20110119/Geron-commences-enrollment-in-imetelstat-Phase-2-clinical-trial-in-essential-thrombocythemia.aspx)
More... (http://www.news-medical.net/news/20110119/Geron-commences-enrollment-in-imetelstat-Phase-2-clinical-trial-in-essential-thrombocythemia.aspx)